ReviewOsteoporosis and sarcopenia2025
Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.
Review in Osteoporosis and sarcopenia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss.Journal of cellular and molecular medicine · 2026Review
- Review
- Real-World Assessment of Osteoporosis-Related Polymorphisms: Negative Findings for Osteoporosis and an Exploratory Association with Vitamin D.Life (Basel, Switzerland) · 2026Article
- Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines sclerostin, a critical regulator of Wnt signaling, focusing on its role in bone homeostasis and its emerging involvement in muscle-bone crosstalk. It examines the regulatory influence of hormones, mechanical stress, and myokines on sclerostin expression under both physiological and pathological conditions. Recent advances underscore sclerostin's role in osteoporosis pathogenesis and its involvement in bone remodeling, while also revealing its emerging significance in muscle-bone communication. Despite these insights, the underlying mechanisms of its regulation remain incompletely understood. By consolidating recent research, this review provides a comprehensive perspective on sclerostin's multifaceted roles and their implications for bone and muscle health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.